Cat. No.
MABL-1862
Application
immunotherapy, WB, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
HD8
From
Recombinant Antibody
Specificity
This antibody specifically binds an epitope comprising amino acids 61-WNSQKDILEQARA-73 in the beta chain of human HLA-DR. This antibody can recognize most polymorphic forms of the human HLA- DR. This antibody can recognize 99.2% of HLA-DRB alleles and also is capable of cross reacting with HLA-DP alleles some HLA-DQ alleles. HLA-DR is an MHC class II cell surface receptor encoded by the human leukocyte antigen complex on chromosome 6 region 6p21.31. HLA-DR is also involved in several autoimmune conditions, disease susceptibility and disease resistance. The primary function of HLA-DR is to present peptide antigens, potentially foreign in origin, to the immune system for the purpose of eliciting or suppressing T-(helper)-cell responses that eventually lead to the production of antibodies against the same peptide antigen.
Alternative Names
CD74; Beta chain HLA-DR; HLA-DR β-chain; β-chain; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33
UniProt
P04233
Immunogen
The original antibody was generated by immunizing a human transgenic KM mice with HLA- DR-expressing L929 cells.
Application Notes
The binding specificity of this antibody to HLA-DR-positive B-lymphoblastoid cell line, SKW6.4 was tested using western blot. The reactivity of this antibody towards various HLA-DR positive cell lines like ARH77, Daudi, Granta519, IM-9, MC/CAR, Raji, RPMI1788, HS-Sultan, Namalwa, RL, Ramos, SKW6.4 etc. was determined using Alexa488 labelled antibody by flow cytometry. This antibody is reported to exert strong antibody dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and significantly extended the life span of immunocompromised mice inoculated with non-Hodgkin lymphoma cell lines. This antibody has potential applications in HLA-DR targeted immunotherapy as it is likely to evoke similarly strong responses in individuals carrying different HLA-DR alleles (PMID: 17428256). The Pro331Ser and Lys322Ala modified version of this antibody was incapable of expressing CDC in vitro and did not induce severe infusion reactions in rats and monkeys, even at extremely high doses. This antibody still retained its Ab-dependent cellular cytotoxicity function as well as its antitumor activity in a tumor-bearing mouse model (PMID: 18250438).
Antibody First Published
Tawara et al. Fully human antibody exhibits pan-human leukocyte antigen- DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.Cancer Sci. 2007 Jun;98(6):921-8. PMID:17428256
Note on publication
Describes the generation and characterization of this antibody.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
